NPY regulation of bone remodelling

Neuropeptides

Volumn 43, Issue 6, 2009, Pages 457-463

  Lee, Nicola J ^a   Herzog, Herbert ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; ISOPRENALINE; LEPTIN; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; NEUROPEPTIDE Y6 RECEPTOR; PEPTIDE YY; UNCLASSIFIED DRUG;

BIOSYNTHESIS; BONE DEVELOPMENT; BONE MASS; BONE METABOLISM; BONE REMODELING; DRUG MECHANISM; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; KNOCKOUT MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW;

ANIMALS; BONE AND BONES; BONE REMODELING; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; NEUROPEPTIDE Y; PHENOTYPE; RECEPTORS, NEUROPEPTIDE Y;

EID: 70350704676     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2009.08.006     Document Type: Review

References (78)

1. Ahmed M., Bjurholm A., Kreicbergs A., and Schultzberg M. Neuropeptide Y, tyrosine hydroxylase and vasoactive intestinal polypeptide-immunoreactive nerve fibers in the vertebral bodies, discs, dura mater, and spinal ligaments of the rat lumbar spine. Spine 18 2 (1993) 268-273
2. Ahn J.D., Dubern B., Lubrano-Berthelier C., Clement K., and Karsenty G. Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology 147 7 (2006) 3196-3202
3. Allison, S., Baldock, P., Enriquez, R., Lin, E., During, M., Gardiner, E., Eisman, J., Sainsbury, A., Herzog, H., 2008. Critical interplay between neuropeptide Y and sex steroid pathways in bone and adipose tissue homeostasis. J. Bone Miner. Res.
4. Allison S.J., Baldock P., Sainsbury A., Enriquez R., Lee N.J., Lin E.J., Klugmann M., During M., Eisman J.A., Li M., Pan L.C., Herzog H., and Gardiner E.M. Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. The Journal of Biological Chemistry 281 33 (2006) 23436-23444
5. Amano S., Arai M., Goto S., and Togari A. Inhibitory effect of NPY on isoprenaline-induced osteoclastogenesis in mouse bone marrow cells. Biochim. Biophys. Acta 1770 6 (2007) 966-973
6. Baldock P.A., Allison S., McDonald M.M., Sainsbury A., Enriquez R.F., Little D.G., Eisman J.A., Gardiner E.M., and Herzog H. Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J. Bone Miner. Res. 21 10 (2006) 1600-1607
7. Baldock P.A., Allison S.J., Lundberg P., Lee N.J., Slack K., Lin E.J., Enriquez R.F., McDonald M.M., Zhang L., During M.J., Little D.G., Eisman J.A., Gardiner E.M., Yulyaningsih E., Lin S., Sainsbury A., and Herzog H. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. The Journal of Biological Chemistry 282 26 (2007) 19092-19102
8. Baldock P.A., Sainsbury A., Allison S., Lin E.J., Couzens M., Boey D., Enriquez R., During M., Herzog H., and Gardiner E.M. Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways. J. Bone Miner. Res. 20 10 (2005) 1851-1857
9. Baldock P.A., Sainsbury A., Couzens M., Enriquez R.F., Thomas G.P., Gardiner E.M., and Herzog H. Hypothalamic Y2 receptors regulate bone formation. J. Clin. Invest. 109 7 (2002) 915-921
10. Baron, R., 1999. Anatomy and ultrastructure of bone. In: Favus, M.F. (Ed.), Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, fourth ed. Lippincott Williams and Wilkins, Philadelphia, PA, pp. 3-10.
11. Bjurholm A. Neuroendocrine peptides in bone. Int. Orthop. 15 4 (1991) 325-329
12. Bjurholm A., Kreicbergs A., Schultzberg M., and Lerner U.H. Parathyroid hormone and noradrenaline-induced enhancement of cyclic AMP in a cloned osteogenic sarcoma cell line (UMR 106) is inhibited by neuropeptide Y. Acta Physiol. Scand. 134 3 (1988) 451-452
13. Bjurholm, A., Kreicbergs, A., Schultzberg, M., Lerner, U.H., 1992. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1, and Saos-2) and primary bone cells. J. Bone Miner. Res. 7(9), 1011-1019.
14. Bjurholm A., Kreicbergs A., Terenius L., Goldstein M., and Schultzberg M. Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues. J. Auton. Nerv. Syst. 25 2-3 (1988) 119-125
15. Blomqvist A.G., and Herzog H. Y-receptor subtypes - how many more?. Trends Neurosci. 20 7 (1997) 294-298
16. Cerda-Reverter J.M., and Larhammar D. Neuropeptide Y family of peptides: structure, anatomical expression, function, and molecular evolution. Biochem. Cell Biol. 78 3 (2000) 371-392
17. Cho Y.R., and Kim C.W. Neuropeptide Y promotes beta-cell replication via extracellular signal-regulated kinase activation. Biochemical and Biophysical Research Communications 314 3 (2004) 773-780
18. Cornish, J., Callon, K.E., King, A.R., Cooper, G.J., Reid, I.R., 1998. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am. J. Physiol. 275(4 Pt 1), E694-E699.
19. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T., Shen J., Vinson C., Rueger J.M., and Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100 2 (2000) 197-207
20. Duong L.T., and Rodan G.A. Regulation of osteoclast formation and function. Rev. Endocrinol. Metab. Disord. 2 1 (2001) 95-104
21. Ekblad E., Edvinsson L., Wahlestedt C., Uddman R., Hakanson R., and Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul. Pept. 8 3 (1984) 225-235
22. Elefteriou F., Ahn J.D., Takeda S., Starbuck M., Yang X., Liu X., Kondo H., Richards W.G., Bannon T.W., Noda M., Clement K., Vaisse C., and Karsenty G. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434 7032 (2005) 514-520
23. Ferron M., Hinoi E., Karsenty G., and Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl. Acad. Sci. USA 105 13 (2008) 5266-5270
24. Gehlert D.R. Introduction to the reviews on neuropeptide Y. Neuropeptides 38 4 (2004) 135-140
25. Gerald C., Walker M.W., Vaysse P.J., He C., Branchek T.A., and Weinshank R.L. Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. The Journal of Biological Chemistry 270 45 (1995) 26758-26761
26. Gordeladze J.O., and Reseland J.E. A unified model for the action of leptin on bone turnover. J. Cell Biochem. 88 4 (2003) 706-712
27. Gregor P., Feng Y., DeCarr L.B., Cornfield L.J., and McCaleb M.L. Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. The Journal of Biological Chemistry 271 44 (1996) 27776-27781
28. Harada S., and Rodan G.A. Control of osteoblast function and regulation of bone mass. Nature 423 6937 (2003) 349-355
29. Henriksen D.B., Alexandersen P., Bjarnason N.H., Vilsboll T., Hartmann B., Henriksen E.E., Byrjalsen I., Krarup T., Holst J.J., and Christiansen C. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J. Bone Miner. Res. 18 12 (2003) 2180-2189
30. Herzog H., Darby K., Ball H., Hort Y., Beck-Sickinger A., and Shine J. Overlapping gene structure of the human neuropeptide Y receptor subtypes Y1 and Y5 suggests coordinate transcriptional regulation. Genomics 41 3 (1997) 315-319
31. Herzog H., Hort Y.J., Ball H.J., Hayes G., Shine J., and Selbie L.A. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc. Natl. Acad. Sci. USA 89 13 (1992) 5794-5798
32. Hill E.L., and Elde R. Distribution of CGRP-, VIP-, D beta H-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res. 264 3 (1991) 469-480
33. Idris A.I., van't Hof R.J., Greig I.R., Ridge S.A., Baker D., Ross R.A., and Ralston S.H. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med. 11 7 (2005) 774-779
34. Ishizuka K., Hirukawa K., Nakamura H., and Togari A. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. Neurosci. Lett. 379 1 (2005) 47-51
35. Johnell O., and Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 17 12 (2006) 1726-1733
36. Keffel S., Schmidt M., Bischoff A., and Michel M.C. Neuropeptide-Y stimulation of extracellular signal-regulated kinases in human erythroleukemia cells. J. Pharmacol. Exp. Ther. 291 3 (1999) 1172-1178
37. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., Shimizu Y., Bronson R.T., Gao Y.H., Inada M., Sato M., Okamoto R., Kitamura Y., Yoshiki S., and Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89 5 (1997) 755-764
38. Kristensen P., Judge M.E., Thim L., Ribel U., Christjansen K.N., Wulff B.S., Clausen J.T., Jensen P.B., Madsen O.D., Vrang N., Larsen P.J., and Hastrup S. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393 6680 (1998) 72-76
39. Kuo L.E., Kitlinska J.B., Tilan J.U., Li L., Baker S.B., Johnson M.D., Lee E.W., Burnett M.S., Fricke S.T., Kvetnansky R., Herzog H., and Zukowska Z. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat. Med. 13 7 (2007) 803-811
40. Larhammar D., Blomqvist A.G., and Soderberg C. Evolution of neuropeptide Y and its related peptides. Comp. Biochem. Physiol. C 106 3 (1993) 743-752
41. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., Dacquin R., Mee P.J., McKee M.D., Jung D.Y., Zhang Z., Kim J.K., Mauvais-Jarvis F., Ducy P., and Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell 130 3 (2007) 456-469
42. Lundberg J.M., Martinsson A., Hemsen A., Theodorsson-Norheim E., Svedenhag J., Ekblom B., and Hjemdahl P. Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochemical and Biophysical Research Communications 133 1 (1985) 30-36
43. Lundberg J.M., Terenius L., Hokfelt T., Martling C.R., Tatemoto K., Mutt V., Polak J., Bloom S., and Goldstein M. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol. Scand. 116 4 (1982) 477-480
44. Lundberg P., Allison S.J., Lee N.J., Baldock P.A., Brouard N., Rost S., Enriquez R.F., Sainsbury A., Lamghari M., Simmons P., Eisman J.A., Gardiner E.M., and Herzog H. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. The Journal of Biological Chemistry 282 26 (2007) 19082-19091
45. Lundberg P., and Lerner U.H. Expression and regulatory role of receptors for vasoactive intestinal peptide in bone cells. Microsc. Res. Tech. 58 2 (2002) 98-103
46. Mackie, K., 2008. Signaling via CNS cannabinoid receptors. Mol. Cell Endocrinol. 286(Suppl. 1-2), S60-S65.
47. Mannon, P.J., Mele, J.M., 2000. Peptide YY Y1 receptor activates mitogen-activated protein kinase and proliferation in gut epithelial cells via the epidermal growth factor receptor. Biochem. J. 350(Pt 3), 655-661.
48. Marks S.C., and Odgren P.R. Structure and development of the skeleton. In: Bilezikian J.P., Raisz L.G., and Rodan G.A. (Eds). Principles of Bone Biology. second ed. (2002), Academic Press, San Diedo, CA 3-15
49. Matsumoto M., Nomura T., Momose K., Ikeda Y., Kondou Y., Akiho H., Togami J., Kimura Y., Okada M., and Yamaguchi T. Inactivation of a novel neuropeptide Y/peptide YY receptor gene in primate species. The Journal of Biological Chemistry 271 44 (1996) 27217-27220
50. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., Cannata J., Balogh A., Lemmel E.M., Pors-Nielsen S., Rizzoli R., Genant H.K., and Reginster J.Y. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350 5 (2004) 459-468
51. Misra M., Miller K.K., Tsai P., Gallagher K., Lin A., Lee N., Herzog D.B., and Klibanski A. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J. Clin. Endocrinol. Metab. 91 3 (2006) 1027-1033
52. Mori T., Ogata T., Okumura H., Shibata T., Nakamura Y., and Kataoka K. Substance P regulates the function of rabbit cultured osteoclast; increase of intracellular free calcium concentration and enhancement of bone resorption. Biochemical and Biophysical Research Communications 262 2 (1999) 418-422
53. Motulsky, H.J., Michel, M.C., 1988. Neuropeptide Y mobilizes Ca2+ and inhibits adenylate cyclase in human erythroleukemia cells. Am. J. Physiol. 255(6 Pt 1), E880-E885.
54. Mundy, G.R., 1999. Bone remodeling. In: Favus, M.F. (Ed.), Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, fourth ed. Lippincott Williams and Wilkins, Philadelphia, PA. pp. 30-38.
55. Nakamura M., Sakanaka C., Aoki Y., Ogasawara H., Tsuji T., Kodama H., Matsumoto T., Shimizu T., and Noma M. Identification of two isoforms of mouse neuropeptide Y-Y1 receptor generated by alternative splicing. Isolation, genomic structure, and functional expression of the receptors. The Journal of biological chemistry 270 50 (1995) 30102-30110
56. Nie M., and Selbie L.A. Neuropeptide Y Y1 and Y2 receptor-mediated stimulation of mitogen-activated protein kinase activity. Regul. Pept. 75-76 (1998) 207-213
57. Otto F., Thornell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., Stamp G.W., Beddington R.S., Mundlos S., Olsen B.R., Selby P.B., and Owen M.J. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89 5 (1997) 765-771
58. Rodan G.A. The development and function of the skeleton and bone metastases. Cancer 97 Suppl. 3 (2003) 726-732
59. Sainsbury A., Baldock P.A., Schwarzer C., Ueno N., Enriquez R.F., Couzens M., Inui A., Herzog H., and Gardiner E.M. Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol. Cell Biol. 23 15 (2003) 5225-5233
60. Sambrook P., and Cooper C. Osteoporosis. Lancet 367 9527 (2006) 2010-2018
61. Sato S., Hanada R., Kimura A., Abe T., Matsumoto T., Iwasaki M., Inose H., Ida T., Mieda M., Takeuchi Y., Fukumoto S., Fujita T., Kato S., Kangawa K., Kojima M., Shinomiya K., and Takeda S. Central control of bone remodeling by neuromedin U. Nat. Med. 13 10 (2007) 1234-1240
62. Shih C., and Bernard G.W. Calcitonin gene related peptide enhances bone colony development in vitro. Clin. Orthop. Relat. Res. 334 (1997) 335-344
63. Sisask G., Bjurholm A., Ahmed M., and Kreicbergs A. The development of autonomic innervation in bone and joints of the rat. J. Auton. Nerv. Syst. 59 1-2 (1996) 27-33
64. Tabarowski Z., Gibson-Berry K., and Felten S.Y. Noradrenergic and peptidergic innervation of the mouse femur bone marrow. Acta Histochem. 98 4 (1996) 453-457
65. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., Armstrong D., Ducy P., and Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 111 3 (2002) 305-317
66. Tam J., Ofek O., Fride E., Ledent C., Gabet Y., Muller R., Zimmer A., Mackie K., Mechoulam R., Shohami E., and Bab I. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol. Pharmacol. 70 3 (2006) 786-792
67. Tam J., Trembovler V., Di Marzo V., Petrosino S., Leo G., Alexandrovich A., Regev E., Casap N., Shteyer A., Ledent C., Karsak M., Zimmer A., Mechoulam R., Yirmiya R., Shohami E., and Bab I. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J. 22 1 (2008) 285-294
68. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc. Natl. Acad. Sci. USA 79 18 (1982) 5485-5489
69. Tatemoto K., Carlquist M., and Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296 5858 (1982) 659-660
70. Teixeira, L., Sousa, D.M., Nunes, A.F., Sousa, M.M., Herzog, H., Lamghari, M., 2009. NPY revealed as a critical modulator of osteoblast function in vitro: new insights into the role of Y1 and Y2 receptors. J. Cell Biochem.
71. Utz A.L., Lawson E.A., Misra M., Mickley D., Gleysteen S., Herzog D.B., Klibanski A., and Miller K.K. Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. Bone 43 1 (2008) 135-139
72. van der Velde M., Delhanty P., van der Eerden B., van der Lely A.J., and van Leeuwen J. Ghrelin and bone. Vitam. Horm. 77 (2008) 239-258
73. van't Hof R.J., Macphee J., Libouban H., Helfrich M.H., and Ralston S.H. Regulation of bone mass and bone turnover by neuronal nitric oxide synthase. Endocrinology 145 11 (2004) 5068-5074
74. Weinberg D.H., Sirinathsinghji D.J., Tan C.P., Shiao L.L., Morin N., Rigby M.R., Heavens R.H., Rapoport D.R., Bayne M.L., Cascieri M.A., Strader C.D., Linemeyer D.L., and MacNeil D.J. Cloning and expression of a novel neuropeptide Y receptor. The Journal of Biological Chemistry 271 28 (1996) 16435-16438
75. Wortley K.E., Garcia K., Okamoto H., Thabet K., Anderson K.D., Shen V., Herman J.P., Valenzuela D., Yancopoulos G.D., Tschop M.H., Murphy A., and Sleeman M.W. Peptide YY regulates bone turnover in rodents. Gastroenterology 133 5 (2007) 1534-1543
76. Xiong Z., and Cheung D.W. ATP-dependent inhibition of Ca2+-activated K+ channels in vascular smooth muscle cells by neuropeptide Y. Pflugers Arch. 431 1 (1995) 110-116
77. Yang K., Guan H., Arany E., Hill D.J., and Cao X. Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB J. 22 7 (2008) 2452-2464
78. Zaidi M. Skeletal remodeling in health and disease. Nat. Med. 13 7 (2007) 791-801